Peanut Allergy Market Analysis: Epidemiology Insights and Therapeutic 

DelveInsight's comprehensive report on "Peanut Allergy Market Insights, Epidemiology, and Market Forecast-2034" delivers extensive understanding of Peanut Allergy, encompassing historical and projected epidemiology alongside market dynamics in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Peanut Allergy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Peanut Allergy Market Forecast https://www.delveinsight.com/sample-request/peanut-allergy-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Key Highlights from the Market Report

• The Peanut Allergy market size was valued at approximately USD 1,648 million in 2023 and is anticipated to expand with a significant CAGR during the study period (2020-2034).

• In December 2025, DBV Technologies is preparing to seek US Food and Drug Administration (FDA) approval once again for its peanut allergy patch after reporting new Phase III results. In the VITESSE trial (NCT05741476), which included 654 children aged 4 to 7 years, the VIASKIN Peanut patch achieved statistically significant benefit. After 12 months of treatment, 46.6% of children receiving the patch were able to tolerate peanut protein exposure, compared with 14.8% in the placebo group.

• In June 2025, DBV Technologies announced its excitement to showcase the latest scientific advancements related to its VIASKIN Registered patch platform at the upcoming EAACI conference—one of the most respected and well-attended events for allergy specialists and thought leaders worldwide. According to Daniel Tasse, Chief Executive Officer of DBV Technologies, the company's symposium will highlight new insights into epicutaneous immunotherapy (EPIT) for peanut allergy, featuring dynamic discussion on the clinical interaction between allergists and patients.

• In March 2025, the US FDA approved OMLYCLO (omalizumab-igec) as the first and only biosimilar recognized as interchangeable with XOLAIR for treating IgE-mediated food allergies.

• In February 2025, Stallergenes Greer, a global leader in allergy treatments, announced the U.S. launch of Palforzia Registered [Peanut (Arachis hypogaea) Allergen Powder-dnfp] for toddlers aged 1 to 3 years diagnosed with peanut allergy. Palforzia Registered is the first and only oral immunotherapy (OIT) approved by the U.S. Food and Drug Administration (FDA) to reduce allergic reactions, including anaphylaxis, due to accidental peanut exposure in patients aged 1 to 17 years.

• In January 2025, the European Commission approved the expanded use of PALFORZIA to include toddlers aged 1-3 with a confirmed Peanut Allergy diagnosis. This marketing authorization applies across all 27 EU member states, as well as the three European Economic Area countries: Iceland, Liechtenstein, and Norway.

• In December 2024, DBV Technologies announced positive outcome from its communication with the FDA, which provided a defined regulatory pathway and formal guidance for the accelerated approval of the Viaskin Peanut Patch for toddlers aged 1-3 years.

• In December 2024, ALK reported encouraging interim findings from its Phase I/II clinical trial (ALLIANCE) evaluating the investigational SLIT tablet for treating Peanut Allergy.

• In 2024, the United States held the largest share of the Peanut Allergy treatment market among the 7MM, with a market size of approximately USD 340 million.

• In 2024, the United States recorded the highest number of diagnosed prevalent cases of Peanut Allergy among the 7MM, with an estimated 5.1 million cases.

• In 2024, Germany reported the highest number of prevalent Peanut Allergy cases among the EU4 and the UK, with around 1,107,000 cases.

• In Japan, the highest number of age-specific Peanut Allergy cases in 2024 was observed in the 41-64 years age group, followed by those aged 65 and older.

• At present, PALFORZIA and XOLAIR are the only approved treatment options for Peanut Allergy, offering two important choices for patients and healthcare professionals. PALFORZIA is approved for children aged 1-3 and 4-17 years, while XOLAIR is authorized for use in individuals aged 1 year and older. As the only oral immunotherapy available, PALFORZIA has certain limitations—its desensitization effect requires ongoing daily dosing to sustain peanut tolerance.

• The Peanut Allergy pipeline is progressing with development of novel therapies featuring diverse mechanisms of action. These include BTK inhibitors like Remibrutinib, immunostimulants such as INP20, immunomodulators like VLP Peanut, immunosuppressants including INT301, and combinations such as cytotoxic T-lymphocyte stimulants with IL-13 receptor blockers (Linvoseltamab + Dupilumab), among others.

• Key pharmaceutical developers include Stallergenes Greer, Roche and Novartis, DBV Technologies, Novartis, ALK-Abello, Aravax, InnoUp Farma, Intrommune Therapeutics, and others.

• Notable therapies comprise PALFORZIA (peanut allergen powder-dnfp), XOLAIR (omalizumab), Viaskin (DBV712) peanut patch, Remibrutinib (LOU064), Sublingual Immunotherapy (SLIT)-Tablet, PVX108 (AVX-201), INP20, INT301, and others.

• The Peanut Allergy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Peanut Allergy pipeline products will significantly revolutionize the Peanut Allergy market dynamics.

Get a Free sample for the Peanut Allergy Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/peanut-allergy-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Understanding Peanut Allergy

Peanut allergy represents a common and potentially severe food allergy in which the immune system mistakenly identifies peanut proteins as harmful. Even small amounts can trigger allergic reactions, ranging from mild symptoms like hives or stomach pain to severe, life-threatening anaphylaxis. It often develops in childhood and can persist into adulthood. Strict avoidance of peanuts and carrying emergency medications like epinephrine are essential for management.

Epidemiological Insights

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides detailed analysis of the diagnosed patient pool and future trends.

Peanut Allergy Epidemiology Segmentation:

The Peanut Allergy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

• Total Prevalence of Peanut Allergy

• Prevalent Cases of Peanut Allergy by severity

• Gender-specific Prevalence of Peanut Allergy

• Diagnosed Cases of Episodic and Chronic Peanut Allergy

Download the report to understand which factors are driving Peanut Allergy epidemiology trends @ Peanut Allergy Epidemiology Forecast

Therapeutic Landscape and Pipeline Development

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the Peanut Allergy market or expected to launch during the study period. The analysis covers Peanut Allergy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares drugs based on market share.

The report also covers Peanut Allergy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Key Peanut Allergy Therapies and Companies:

• PALFORZIA (peanut allergen powder-dnfp): Stallergenes Greer

• XOLAIR (omalizumab): Roche and Novartis

• Viaskin (DBV712) peanut patch: DBV Technologies

• Remibrutinib (LOU064): Novartis

• Sublingual Immunotherapy (SLIT)-Tablet: ALK-Abello

• PVX108 (AVX-201): Aravax

• INP20: InnoUp Farma

• INT301: Intrommune Therapeutics

Discover more about therapies set to grab major Peanut Allergy market share @ Peanut Allergy Treatment Landscape

Market Dynamics

Peanut Allergy Market Drivers

• Increasing prevalence of food allergies

• Growth in commercial and scientific activities for research and development

• Expanding diagnostic capabilities and awareness

Peanut Allergy Market Barriers

• Lack of public awareness

• Challenges in accurate diagnosis of food allergies

• Limited treatment options currently available

Report Scope

• Study Period: 2020-2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Companies: Stallergenes Greer, Roche and Novartis, DBV Technologies, Novartis, ALK-Abello, Aravax, InnoUp Farma, Intrommune Therapeutics, and others

• Key Therapies: PALFORZIA (peanut allergen powder-dnfp), XOLAIR (omalizumab), Viaskin (DBV712) peanut patch, Remibrutinib (LOU064), Sublingual Immunotherapy (SLIT)-Tablet, PVX108 (AVX-201), INP20, INT301, and others

• Therapeutic Assessment: Current marketed and emerging therapies

• Market Dynamics: Market drivers and barriers

• Competitive Intelligence: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

• Additional Coverage: Unmet Needs, KOL's views, Analyst's views, Market Access and Reimbursement

To know more about Peanut Allergy companies working in the treatment market, visit @ Peanut Allergy Clinical Trials and Therapeutic Assessment

Table of Contents

1. Peanut Allergy Market Report Introduction

2. Executive Summary for Peanut Allergy

3. SWOT analysis of Peanut Allergy

4. Peanut Allergy Patient Share (%) Overview at a Glance

5. Peanut Allergy Market Overview at a Glance

6. Peanut Allergy Disease Background and Overview

7. Peanut Allergy Epidemiology and Patient Population

8. Country-Specific Patient Population of Peanut Allergy

9. Peanut Allergy Current Treatment and Medical Practices

10. Peanut Allergy Unmet Needs

11. Peanut Allergy Emerging Therapies

12. Peanut Allergy Market Outlook

13. Country-Wise Peanut Allergy Market Analysis (2020-2034)

14. Peanut Allergy Market Access and Reimbursement of Therapies

15. Peanut Allergy Market Drivers

16. Peanut Allergy Market Barriers

17. Peanut Allergy Appendix

18. Peanut Allergy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight operates as a premier Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us

Kanishk

kkumar@delveinsight.com